These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24522741)

  • 1. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
    Hocking CM; Kichenadasse G
    Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
    Wang XF; Feng Y; Chen Y; Gao BL; Han BH
    Sci Rep; 2014 Apr; 4():4813. PubMed ID: 24770591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
    Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
    Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
    Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C
    Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Meena JP; Gupta AK; Jat KR; Anandani G; Sasidharan A; Tanwar P
    J Pediatr Hematol Oncol; 2023 Oct; 45(7):361-369. PubMed ID: 37539996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
    Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
    Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
    Yoodee J; Permsuwan U; Nimworapan M
    Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
    Tan L; Liu J; Liu X; Chen J; Yan Z; Yang H; Zhang D
    J Exp Clin Cancer Res; 2009 Sep; 28(1):131. PubMed ID: 19775450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.
    DeRemer DL; Clemmons AB; Orr J; Clark SM; Gandhi AS
    Pharmacotherapy; 2016 Feb; 36(2):218-29. PubMed ID: 26890915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM; Nagy CK; Gray SE
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.
    Alhifany AA; McBride A; Almutairi AR; Cheema E; Shahbar A; Alatawi Y; Alharbi AS; Babiker H; MacDonald K; Aapro M; Abraham I
    Support Care Cancer; 2020 Mar; 28(3):1031-1039. PubMed ID: 31823054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
    Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
    Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.
    Navari RM
    Biomed Res Int; 2015; 2015():595894. PubMed ID: 26421294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
    Wang SY; Yang ZJ; Zhang L
    Asian Pac J Cancer Prev; 2014; 15(22):9587-92. PubMed ID: 25520071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials.
    Zhou JG; Huang L; Jin SH; Xu C; Frey B; Ma H; Gaipl US
    ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
    Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
    Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.